Moderna, Inc. (NASDAQ:MRNA) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its stake in Moderna, Inc. (NASDAQ:MRNAFree Report) by 7.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 455,407 shares of the company’s stock after selling 37,691 shares during the quarter. New York State Common Retirement Fund’s holdings in Moderna were worth $45,290,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. The Manufacturers Life Insurance Company increased its position in Moderna by 77.3% in the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after buying an additional 1,690,341 shares during the period. Invesco Ltd. lifted its holdings in shares of Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after buying an additional 517,683 shares during the period. Wellington Management Group LLP boosted its stake in Moderna by 9.3% during the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after buying an additional 476,201 shares in the last quarter. Bamco Inc. NY raised its position in Moderna by 4,863.6% in the third quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock worth $44,091,000 after acquiring an additional 418,269 shares in the last quarter. Finally, abrdn plc lifted its holdings in Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after acquiring an additional 399,843 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the transaction, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Moderna news, CFO James M. Mock sold 647 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the transaction, the director now directly owns 2,101,931 shares of the company’s stock, valued at approximately $229,236,594.86. The disclosure for this sale can be found here. Insiders sold 109,954 shares of company stock valued at $11,533,976 in the last three months. Corporate insiders own 15.70% of the company’s stock.

Moderna Price Performance

Shares of MRNA opened at $108.85 on Thursday. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $142.79. The company’s fifty day simple moving average is $101.85 and its 200 day simple moving average is $93.64. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.

Moderna (NASDAQ:MRNAGet Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. Moderna’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same quarter last year, the business posted $3.61 EPS. As a group, analysts expect that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent analyst reports. HSBC restated a “reduce” rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a report on Tuesday, January 2nd. Finally, Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $126.49.

Check Out Our Latest Stock Report on Moderna

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Articles

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.